HeartSciences
HeartSciences is focused on applying innovative AI-based technology to an ECG.
We have news: HeartSciences (NASDAQ:HSCS) Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG
The study commenced in 2021 and is a prospective, multi-center study to validate the diagnostic performance of the MyoVista wavECG AI algorithm for the detection of impaired left ventricular relaxation. The study has enrolled more than 600 patients at five geographically dispersed centers located across the United States and the data will now undergo verification and analysis which, assuming positive results, will be incorporated as part of the Company’s FDA De Novo submission for the MyoVista.
Andrew Simpson, CEO of HeartSciences (NASDAQ:HSCS), stated, “The emerging field of AI ECG offers the meaningful prospect of low-cost screening to help solve the diagnostic gap where millions of people with heart disease remain undiagnosed until some sort of cardiac event, such as a heart attack. We have invested years in artificial intelligence R&D and have designed our first product, the MyoVista, to detect cardiac dysfunction at an early stage.
Millions of ECGs are performed every week and we look forward to leading the commercialization of new AI ECG indications for use to make the ECG a far more valuable cardiac test. We are grateful to the clinical institutions and physicians involved in our pivotal study for their diligent work over the past couple of years. We are delighted to have concluded patient enrollment which has been by far the most time-consuming part of our FDA De Novo submission process.”
Almost all forms of heart disease affect heart muscle, or cardiac, function including prior to symptoms. Impaired cardiac function is first observed as impaired left ventricular (LV) cardiac relaxation, an early indicator of LV diastolic dysfunction that increases in severity as heart disease progresses and is also associated with age-related cardiac dysfunction. As Kitzman and Little pointed out in their 2012 paper published in Circulation, “LV diastolic function is impaired by all the common pathological processes that affect LV function or produce LV hypertrophy or fibrosis, including hypertension, diabetes mellitus, ischemia, myocarditis, toxins, and infiltrative cardiomyopathies. Thus, LV diastolic performance is a sensitive indicator of cardiovascular dysfunction (2).”
About HeartSciences�Heart Test Laboratories, Inc. d/b/a HeartSciences is a next-generation, AI electrocardiogram (AI ECG) company focused on using AI to transform the ECG (also known as the EKG) to save lives through earlier detection of heart disease. Millions of ECGs are performed every week and AI is creating a new era of opportunity for the ECG with recent AI ECG applications described as, “some of the most significant advances in electrocardiography since its inception(1).” The Company’s objective is to become a fixture in front-line healthcare settings to help physicians make better and earlier referral decisions for at-risk patients.
Notes
(1) Khurram Nasir, MD, MPH, MSC,et. al., Journal of American College of Cardiology Editorial Comment Volume 76 Number 8 2020.
(2) Dalane W. Kitzman and William C. Little, Circulation Volume 125 Issue 6 2012.
Safe Harbor Statement�
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences’ beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences’ filings with the U.S. Securities and Exchange Commission at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
See the full release: https://www.globenewswire.com/news-release/2023/05/09/2664416/0/en/HeartSciences-Announces-Completion-of-Patient-Enrollment-for-FDA-Pivotal-Study-of-MyoVista-wavECG.html
05/08/2023
CEO event this week in New York: HeartSciences (NASDAQ:HSCS) to Participate at the EF Hutton Global Conference May 10–11 at the Plaza Hotel in New York City
Register now and request a 1x1 meeting with Andrew Simpson Thursday, May 11:
https://efhconference.com/investor-registration
Read the official announcement:
https://ir.heartsciences.com/heartsciences-to-participate-at-the-inaugural-ef-hutton-global-conference/
Every 40 seconds, someone dies of heart disease. Millions of people go undiagnosed because a valve issue, enlarged heart or coronary arterial disease often doesn't affect heart rhythm until an acute stage. Learn why an AI-enabled ECG might help in the future. Here's the transcript of a new 🎤 Interview with HeartSciences CEO Andrew Simpson:
[Host]: So are you saying that there's currently no current frontline medical device that is effective at screening for heart disease?
[AS]: I'm not saying that. The entire medical community is.
[Host]: No kidding.
[AS] So, if you want to be tested today, the tests are in cardiology. And they're cardiac imaging tests like CT scanners or echocardiograms. The frontline physician has a risk assessment: Are you overweight? Do you have a family history? Those kind of questions. And that's essentially what he [the frontline physician] has today.
The ECG, as I say, misses most forms of heart disease because it was invented over a hundred years ago and it's got very low specificity.
[Host]: What's happening?
[AS]: Go on.
[Host]: So at the end of the day, millions of people with heart disease go undiagnosed. Isn't that the end result, correct?
[AS]: Literally millions and millions of people. And it's costing the system about half a trillion dollars a year. I mean, every 40 seconds somebody dies of heart disease in the United States.
[Host]: So when I go on my Apple Watch and I hit ECG, which gives me an electrocardiogram or – whatever their version is – and I look at it, it'll say sinus rhythm, which is a good thing.
Or it'll say – if I do it right in the middle of exercise – it’ll say high heart rate, but no sign of atrial fibrillation. Or for some people it'll say atrial fibrillation, but that doesn't tell me if I'm having a heart attack or have heart disease. It's just basically giving me top-down data, correct?
[AS]: Well, the conventional trace is a time and voltage trace which is essentially an analog waveform like an oscilloscope, so it is providing you heart rhythm information, and it's great for heart rhythm information.
The big problem is if you’ve got a valve issue or an enlarged heart, or you've got coronary arterial disease, it's just not often going to affect the rhythm of the heart until an acute stage. Or even until after you've had a heart attack, which is why the ECG is just missing today most forms of heart disease.
Learn more: https://heartsciences.com
05/02/2023
📢 CEO Event: Join us this Thursday May 4, 2023 👨⚕️ HeartSciences (NASDAQ:HSCS) CEO Andrew Simpson to Participate in The Benchmark Company’s Virtual Individual Investor Healthcare Conference
Register Now → https://us02web.zoom.us/meeting/register/tZEsd--rqzgsHdRyYPXnsn2EHxPKEDf3YH6s #/registration
Details of the announcement →
https://ir.heartsciences.com/heartsciences-to-participate-in-the-benchmark-companys-virtual-individual-investor-healthcare-conference/
We were curious about what ChatGPT knows about patents related to AI-enabled ECGs.
HeartSciences (NASDAQ:HSCS) is in good company, as ChatGPT provided three examples of patents from GE HealthCare, Philips and HeartSciences.
Here is ChatGPT’s complete response:
There are numerous patents filed in connection with AI-enabled ECGs, and it would be impossible to list them all here. However, here are a few examples:
US Patent No. 10,200,028 - “System and method for automated electrocardiogram interpretation using deep neural networks.” This patent, filed by General Electric, describes a system that uses deep neural networks to interpret ECG signals and classify them based on a set of predetermined criteria.
US Patent No. 10,924,044 - “Method and apparatus for automated cardiac arrhythmia detection and classification using neural networks.” This patent, filed by Philips Healthcare, describes a system that uses neural networks to detect and classify cardiac arrhythmias in ECG signals.
US Patent No. 10,301,289 - “Computer-implemented method for predicting cardiac function using machine learning algorithms.” This patent, filed by HeartSciences (NASDAQ:HSCS), describes a method for predicting cardiac function using machine learning algorithms that analyze ECG signals.
These are just a few examples, and there are many other patents filed by various companies and organizations in connection with AI-enabled ECGs.
04/23/2023
Don't miss this Wednesday’s webcast presentation with HeartSciences CEO Andrew Simpson 🌐 Wednesday, April 26 • 11:00 am – 11:30 am Pacific Time
Register Now:
https://webcaster4.com/Webcast/Page/2963/47983
04/17/2023
📅 Save the date: HeartSciences (NASDAQ:HSCS) CEO Andrew Simpson to Present at the Planet MicroCap Showcase: VEGAS 2023
CEO Andrew Simpson will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023. The conference is being held on April 25 – 27, 2023 at the Horseshoe Hotel & Casino (formerly Bally’s) in Las Vegas, NV.
Presentation Date: April 26, 2023
Time: 11:00 am Pacific ⏰
Mr. Simpson will be available for one-on-one meetings at the conference venue.
To request a meeting with Andrew Simpson and register for the conference: https://planetmicrocapshowcase.com/signup
Attend the webcast: https://www.webcaster4.com/Webcast/Page/2963/47983
Read the announcement → https://www.globenewswire.com/news-release/2023/04/17/2647912/0/en/HeartSciences-to-Present-at-the-Planet-MicroCap-Showcase-VEGAS-2023.html
03/16/2023
We have news: HeartSciences (NASDAQ:HSCS) Provides Business Update and Reports Third Quarter Fiscal 2023 Financial Results
Key Milestones:
✓ Engaged in multi-year collaboration with Rutgers University to develop AI-based ECG algorithms 🏫
✓ Further international patents granted, bringing total patent portfolio to 40 (nine U.S., 31 internationally) 🔒
✓ Balance sheet strengthened through the amendment and exercise of pre-IPO bridge warrants, $15 million equity facility and extension of the maturity dates on investor loans 💪
Andrew Simpson, CEO, stated: “We continue to diligently work towards commercialization of the MyoVista®, with a key focus on our resubmission for FDA De Novo clearance. The enrollment for our pivotal validation study is progressing and device testing is underway. In addition, as previously reported, we have also enrolled additional enrichment study patients to provide extra data and we continue to carefully manage our cash as we progress towards our goal of FDA De Novo resubmission in the current calendar year, assuming positive results.”
“We believe HeartSciences’ is at the leading edge of bringing new clinical capabilities to the ECG. The problem we’re seeking to solve is well known. Millions of people with heart disease remain undiagnosed until some sort of event that could have been preventable through early detection. That’s why our MyoVista® device is designed to significantly increase the clinical value of the ECG by detecting cardiac dysfunction at an early stage. Our objective is to become a fixture in front-line healthcare settings to help physicians make better and earlier referral decisions for at risk patients.”
Read the release → https://www.globenewswire.com/news-release/2023/03/16/2629198/0/en/HeartSciences-Provides-Business-Update-and-Reports-Third-Quarter-Fiscal-2023-Financial-Results.html
Scripps News asked HeartSciences CEO Andrew Simpson about what future improvements in EKG technology could mean for patients and their quality of life and length of life.
Andrew Simpson says that one day it might be possible to get an ECG test at a Walmart Health or other frontline environment that could determine whether you've got heart disease. Currently there is no such test, which is why most people in the US find out that have heart disease through a heart attack or other adverse event.
Our CEO Andrew Simpson recently caught up with Scripps News about how Artificial Intelligence is making its mark in the field of medicine, and the potential impact AI might have on a new era of EKGs.
02/28/2023
We are proud to be highlighted as one of the solutions in our work with the Center for Innovation at Rutgers Robert Wood Johnson University Hospital.
Read the article →
Excitement building: RWJUH, med school combine for Center for Innovation that’s growing, inspiring | ROI-NJ Leaders of Robert Wood Johnson University Hospital‘s and Rutgers Robert Wood Johnson Medical School‘s new Center for Innovation say they’re moving at a rapid pace. The numbers speak for themselves. When the two local medicine titans brought the research center to life in September, they announ...
February is American Heart Month, which means it is time to heighten awareness about the risk factors for heart disease and the steps everyone can take to live a heart-healthy lifestyle.
In this video, HeartSciences (NASDAQ:HSCS) CEO Andrew Simpson describes how improving the referral process is key to improving patient outcomes and reducing costs associated with cardiovascular disease.
Have a listen 🔈
Part 2 of new 📺 TV Interview with HeartSciences (NASDAQ:HSCS) CEO Andrew Simpson
A heart attack is not a good way to find out you’ve got heart disease.
Most people – including TV host Robert “Sully” Sullivan – are surprised to learn that heart disease is more deadly than *all* cancers combined.
Andrew Simpson explains how HeartSciences is approaching the biggest spend in healthcare around the world and in the US.
Full interview available → https://ir.heartsciences.com
New 📺 TV Interview on The Big Biz Show featuring HeartSciences CEO Andrew Simpson.
We’re working to change what’s possible with an ECG so that it can detect cardiac dysfunction at an early stage. This has been described as “one of the most significant advances in electrocardiography since its inception”
02/06/2023
We have more news: HeartSciences has been granted a key Israeli international patent for our MyoVista® Wavelet technology utilizing artificial intelligence (AI) for early detection of heart disease
→ Israeli patent covers a country known as a hotbed for medical device innovation
Full text of today’s announcement:
Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of Artificial Intelligence (AI), today announced it has been granted a patent in Israel (Patent No. 10-2490960) from the Israel Patent Office.
Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “Artificial intelligence is transforming what’s possible, and at HeartSciences we are at the leading edge of changing what’s possible with an ECG by applying AI to make it a far more valuable screening tool for heart disease detection to save lives. Israel is a hotbed for medical device innovation, with more patents granted per capita than anywhere else worldwide. This patent award further protects our IP and further validates our position as a technology innovator. Protection of our intellectual property and patents is core to our strategy as they provide intrinsic value and would be expected to be a source of major competitive advantage as we move toward commercialization.”
Millions of ECGs are performed worldwide every week and the ECG is by far the most ubiquitous cardiac test. Despite this, cardiovascular disease accounts for 17.9 million deaths annually, an estimated 32% of all deaths worldwide. The MyoVista® provides all conventional ECG information but, in addition, incorporates an AI algorithm for the detection of cardiac dysfunction. Conventional ECGs have historically had a limited, if any, role in the evaluation of cardiac dysfunction which has significantly reduced their role for heart disease screening.
To date, HeartSciences has been granted nine US patents and 31 international patents for a total of 40 granted patents. The Company has 8 additional patents pending across the US and international markets. Issued international patents are across key countries including China, Brazil, Canada, India, South Korea, Mexico, and key European markets such as Germany, France, the UK, Italy and the Netherlands.
About HeartSciences
Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical usefulness. Millions of ECGs are performed every week and the Company’s objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences’ first product candidate for FDA clearance, the MyoVista® wavECG, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test. The business model, which involves the use of the MyoVista® device and consumables for each test, is expected to be “razor-razorblade” as the electrodes used with the MyoVista® are proprietary to HeartSciences, and new electrodes are required for every test performed.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences’ beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences’ filings with the U.S. Securities and Exchange Commission at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Please read the full release and disclosures → https://www.globenewswire.com/news-release/2023/02/06/2601964/0/en/HeartSciences-Granted-Key-Israeli-International-Patent-for-its-MyoVista-Wavelet-Technology-Utilizing-Artificial-Intelligence-AI-for-Early-Detection-of-Heart-Disease.html
02/03/2023
🚨 We have news: HeartSciences Announces Further Internationalization of its Patent Portfolio → Granted Korean Patent for its MyoVista® Wavelet Technology
Southlake, Texas, Feb. 03, 2023 — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of Artificial Intelligence (AI), today announced it has been granted Korean Patent No. 10-2490960 from the Korean Intellectual Property Office (KIPO).
To date, HeartSciences has been granted nine US patents and 30 international patents for a total of 39 granted patents. The Company has nine additional patents pending across the US and international markets. Issued international patents are across key countries including China, Brazil, Canada, India, South Korea, Mexico, and key European markets such as Germany, France, UK, Italy and the Netherlands.
Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “Millions of ECG’s are performed worldwide every week and the ECG is by far the most ubiquitous cardiac test. The addition of cardiac dysfunction detection to the ECG is expected to provide significant benefit to healthcare providers and health systems around the world. Cardiovascular disease accounts for 17.9 million deaths, an estimated 32% of all deaths worldwide. The MyoVista® could play a significant role in heart health screening worldwide.”
Mr. Simpson continued, “Given the scale of the global market, protection of our intellectual property and patents in major markets is core to the Company as it provides intrinsic value to HeartSciences and would be expected to be a source of major competitive advantage as we move toward commercialization. This latest patent further expands our international coverage and is the latest addition to our extensive patent portfolio.”
The MyoVista® is a resting 12-lead electrocardiograph that uses AI and continuous wavelet transform (CWT) signal processing to provide cardiac information associated with left ventricular diastolic dysfunction (LVDD), a condition which has previously not been possible to detect using conventional electrocardiology.
It is designed to improve the ability of electrocardiography by using continuous wavelet transform mathematics to extract the frequency content from the input ECG signal. This additional valuable information is used as part of the input in developing the AI models and helps improve overall model performance.
Read the official news release: https://ir.heartsciences.com/heartsciences-announces-further-internationalization-of-its-patent-portfolio/
🎙️ New Interview with HeartSciences CEO Andrew Simpson. Mr. Simpson discusses what’s ahead for HeartSciences and how we’re applying advanced science and artificial intelligence to the ECG to make it a much more valuable screening tool.
Here's a partial transcript of the interview:
[Host]: And joining me now is Andrew Simpson. He’s the CEO of Heart Sciences. Maybe give us a bit of an overview of HeartSciences.
[Andrew Simpson] We’ve been working to advance the ECG. Everybody’s heard of the ECG or in the US it’s called an EKG, but people think that it’s a screening tool for heart disease, but actually it’s an incredibly poor tool because it misses most forms of heart disease.
So we’ve been applying advanced science and artificial intelligence to the ECG to make it a much more valuable screening tool, particularly in a frontline environment so that it would be able to pick up heart disease.
[Host] Maybe talk a bit about the technology and how that works.
[Andrew Simpson] So it’s quite simple really. When you have an EKG, you take the electrical signal from the heart, and the normal display you see is just really a voltage signal over time. So, you know, imagine sticking a volt meter in your house. It’s a very simple technology.
We take that electrical signal and then we basically extract thousands and thousands of extra data points from that electrical signal. And that’s why you need to use artificial intelligence - is to analyze those data points. And then essentially you’re able to pick up much more forms of heart disease than a conventional ECG would.
[Host] So Andrew – is this – would this be used in a hospital setting, or would this be used when you go for a heart test and things like that? Or is it a combination of both?
[Andrew Simpson] It could be anywhere. But look – if you go to a cardiologist, he’s got MRI scanners, CT scanners. He’s got a range of imaging equipment.
Where the ECG would be most valuable is in frontline environments where the primary care physician doesn’t have a test to tell you if you’ve got heart disease. So why does everybody know of somebody who’s had a heart attack unexpectedly or even died unexpectedly? Because there’s no test in the frontline.
So this can be used in any frontline environment. Now that could be primary care, it could be Walmart Health, it could be the ER room, it could be your endocrinologist if you’re diabetic. Think of anywhere that heart testing would be valuable in really a pre-cardiology environment.
And look – there’s estimates of a billion ECG tests undertaken around the world every year. In the US there’s more than a hundred million. So, you know, already, there’s enormous ECG testing, but it doesn’t have a lot of value today or has less value than it should.
For the full interview and related article, please visit:
https://www.proactiveinvestors.com/companies/news/1004693/heartsciences-using-technology-to-help-make-lifesaving-ecg-s-better-using-artificial-intelligence-1004693.html?viewSource=SkyAlphabet
01/20/2023
Don’t miss the fireside chat with our CEO Andrew Simpson and analyst Allen Klee of Maxim Group at 11:00 a.m. Eastern Time on Wednesday, January 25th.
📆 To reserve your seat for the event, please register for the conference here → https://m-vest.com/events/healthcare-it-01252023
01/08/2023
We are pleased to announce that we have appointed David R. Wells to our Board of Directors, effective December 28, 2022.
Andrew Simpson, Chief Executive Officer of HeartSciences, stated, “We are pleased to welcome David Wells to our Board of Directors who has a track record working with, and as CFO for, public and private companies and brings considerable finance and capital markets experience. David has experience with medical technology, startups and rapid growth companies which will be important as we advance towards commercialization following completion of our validation study and FDA De Novo resubmission.”
Mr. Wells brings over 30 years of senior financial management experience. Most recently, he founded Atlas Bookkeeping, LLC, a technology-based financial services firm that provides bookkeeping and reporting services for emerging growth and small cap public and privately held companies. Prior to Atlas, Mr. Wells served as Chief Financial Officer of GHS Investments, LLC, a privately held “super value” fund focused on investing in small-to-mid cap companies. Mr. Wells also served as Chief Financial Officer of ENDRA Life Sciences (Nasdaq: NDRA), a publicly traded clinical diagnostics technology company.
Mr. Wells directed ENDRA’s initial public offering and subsequently helped raise an additional $55 million across multiple transactions. Previously, David founded Wells Compliance Group, a technology-based services firm supporting the financial reporting needs of publicly traded companies and privately held firms. Additionally, David held numerous Chief Financial Officer, Vice President of Finance, and Senior Business Analyst positions. David began his career as a consultant to various start-up and growing companies. David holds a Master of Business Administration from Pepperdine University with a focus in Finance and a Bachelor of Science degree in Finance and Entrepreneurship from Seattle Pacific University.
About HeartSciences
Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical usefulness. Millions of ECGs are performed every week and the Company’s objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences’ first product candidate for FDA clearance, the MyoVista® wavECG, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging.
See the release ➜ https://www.globenewswire.com/news-release/2023/01/04/2582963/0/en/HeartSciences-Appoints-David-R-Wells-to-its-Board-of-Directors-an-Experienced-Capital-Markets-and-Finance-Executive.html
Million of ECGs are performed worldwide every week. According to Allied Market Research, advanced technology for ECG devices is expected to drive growth at a CAGR of 8.3% to reach $18.4 Billion by 2030. The segment with the largest expected growth is the Hospitals and Clinics segment. Source → https://alliedmarketresearch.com/electrocardiograph
Click here to claim your Sponsored Listing.
Videos (show all)
Category
Contact the practice
Telephone
Website
Address
550 Reserve Street, Suite 360
Southlake, TX
76092
Love Rises
Southlake, 76092
Dr. Hutcheson helps you live in an authentic world. She believes that through the love of Jesus Christ, you can rise above the current minutiae of the day and enjoy a place of pea...
The Super Patch Company
Southlake, 76092
Take control of your health care costs with open enrollment throughout the year.
Global Open Wound Care
521 W Southlake Boulevard
Southlake, 76092
Mobile Open Wound Care. Providing noninvasive yet highly effective open wound treatment.
EvaHealth
Southlake
We help cash medical practices foster better patient outcomes in a fraction of the time while boosting fiscal health!
HealthRecon Connect
550 Reserve Street Suite 190 & 250, #21
Southlake, 76092
HealthRecon Connect LLC provides technology-enabled Revenue Cycle Management solutions to US healthcare providers.
Texas Thyroid - Texas ENT Specialists
2813 W. Southlake Boulevard #150
Southlake, 76092
Over 50 Years Combined Thyroid Surgical Experience Committed to Excellence Innovation - Leadership - Quality
Baylor Scott & White Surgicare Southlake
905 E. Southlake Boulevard
Southlake, 76092
We focus on offering a high quality, service oriented environment for your surgical procedure.
AMPM Virtual Staffing LLC
1560 E Southlake Boulevard Ste 100
Southlake, 76092
A US Based Company that specializes in business processing outsourcing for medical practices.
Longevity Texas
2920 W Southlake Boulevard, Suite 120
Southlake, 76092
Top non-invasive FACIAL treatments. Hydrafacial MD, SkinPen, Revision Skincare, ZO Skincare, Botox.